Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Completed 4No longer available 2Not yet recruiting 1

Sponsor Class

OTHER 9INDUSTRY 7NETWORK 1

Study Type

Interventional 3Observational 2Expanded_access 2

Sponsor

Cancer Type

Sarcoma 7Gastrointestinal 7

Conditions

Colorectal Neoplasms 42Neoplasms 14Carcinoma, Hepatocellular 9Gastrointestinal Stromal Tumors 7Liver Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Astrocytoma 2Advanced Cancer 2Wilms Tumor 1Uterine Cervical Neoplasms 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Malignant Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Physician Education 1Pancreatic Neoplasms 1Neuroblastoma 1Melanoma 1

Interventions

Imatinib Mesylate 26Sunitinib 22nilotinib 12ripretinib 11regorafenib 7avapritinib 7tanespimycin 2pexidartinib 2masitinib 2famitinib 2Midazolam 2IDRX-42 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2umbralisib 1trastuzumab deruxtecan 1trametinib 1tinostamustine 1spartalizumab 1ribociclib 1repaglinide 1ponatinib 1perifosine 1pembrolizumab 1olverembatinib 1olaratumab 1motesanib diphosphate 1dabrafenib 1cediranib 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Stromal Tumors × regorafenib × Clear all
NCT07379047 2026-04-24

GISTAR-1

Ningbo Newbay Technology Development Co., Ltd

Phase 2/3 Not yet recruiting
255 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02106858 2023-07-24

StivargaPMS

Bayer

Completed
316 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT03465722 2022-10-06

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

Blueprint Medicines Corporation

Phase 3 Completed
476 enrolled 14 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01933958 2022-04-01

Regorafenib Post-marketing Surveillance in Japan

Bayer

Completed
72 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01271712 2021-01-29

GRID

Bayer

Phase 3 Completed
199 enrolled 17 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01689376 2016-08-16

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)

Bayer

No longer available
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01646593 2014-12-15

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

Bayer

No longer available
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡